Promethera Biosciences is headquartered in the Walloon region of Belgium. Located at the Belgian site are GMP certified manufacturing facilities. Its US subsidiary, Promethera Biosciences LLC, has facilities in Durham, NC, US. These include commercial operations; GMP certified manufacturing facilities and the organ procurement relations department. The site in Basel, Switzerland is focused on developing Atrosimab and other antibody programs based on a proprietary platform. The branch office in Tokyo, Japan, focuses on increased Business Development, Investor Relations activities and expansion of its business and products pipeline in Asia.
Belgian Head Office
On the 1.200m2 site of the Promethera head office, it has 420m2 GMP-certified manufacturing facilities. This includes three grade B aseptic rooms, clean rooms, dedicated Quality Control areas and R&D laboratories and stock and warehouse areas. The facilities were accredited to a GMP standard by the Belgian authorities. The Company also has the capacity to expand its manufacturing activities.
Durham, NC, US Manufacturing
Promethera has a certified GMP manufacturing facility of 7500 sq ft, based in Durham, NC, US. This operation works closely with the U.S. Organ Procurement Organizations (OPO) to obtain healthy, non-transplantable human livers. The Promethera US manufacturing facilities are in compliance with both U.S. and EU GMP regulations.
In April 2018, Promethera announced the acquisition of Baliopharm AG, a Swiss biopharmaceutical company focused on the development of targeted biological therapies for immune mediated inflammatory diseases and cancer. Through this transaction, Promethera gained control over Baliopharm’s site and antibody development programs including the next-generation and selective TNF-R1 inhibitor Atrosimab. The site continued to operate as a center pf excellence for the company’s antibody-related drug development activities.
Promethera’s branch office in Japan was established in May 2018 as the starting point for building a strong presence in Japan and the wider Asian markets. The Asian markets, and particularly the Japanese one, regard cell therapy positively and represent a special opportunity for Promethera’s products and corporate development activities. Mutsuki Takano, Group CFO and Member of the Management Team of Promethera Biosciences SA, serves as the Branch General Manager of Promethera Biosciences Japan Branch.